<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6660">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996307</url>
  </required_header>
  <id_info>
    <org_study_id>V112_06</org_study_id>
    <nct_id>NCT00996307</nct_id>
  </id_info>
  <brief_title>Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to &lt;36 Months</brief_title>
  <official_title>Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1) 2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to &lt;36 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immunogenicity of different combinations of A/H1N1
      2009 (swine flu) vaccine in healthy young children
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Antibody Responses After the First and Second Vaccinations</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two-sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.
CHMP Criteria: Percentage of subjects with seroconversion for HI antibody is &gt;40%; percentage of subjects achieving an HI titer ≥1:40 is &gt; 70%; and the Geometric Mean Ratio (GMR) is &gt;2.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</measure>
    <time_frame>Day 1 to 7</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</measure>
    <time_frame>Day 22 to 28</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Measurement by Geometric Mean Titers (GMT)</measure>
    <time_frame>21 days after each vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The two-sided confidence intervals (CIs) were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667.(based on CBER guidance against the licensed comparator). Moreover the superiority hypothesis was tested using a margin of 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</measure>
    <time_frame>Past 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</measure>
    <time_frame>Past 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Response Based on Baseline Seropositivity</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Persistence 6 Months and 12 Months After the Second Vaccination</measure>
    <time_frame>6 months and 12 months after second vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Persistence by Geometric Mean Titers (GMT)</measure>
    <time_frame>6 months and 12 months after second vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(0)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5_(50)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15_(0)MF59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>3.75_(50)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>7.5_(0)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>15_(0)MF59</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MF59-eH1N1_f</intervention_name>
    <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
    <arm_group_label>7.5_(50)MF59</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children 6 to 35 months of age in good health as determined by medical history,
             physical assessment and clinical judgement of the investigator and without influenza
             within the past 6 months

        Exclusion Criteria:

          -  History of serious disease.

          -  History of serious reaction following administration of vaccine or hypersensitivity
             to vaccine components.

          -  Known or suspected impairment/alteration of immune function.

          -  Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week
             before or after each study vaccination

        For additional entry criteria, please refer to protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dinuba</city>
        <state>California</state>
        <zip>93618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woburn</city>
        <state>Massachusetts</state>
        <zip>01801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartansburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delegacion Tlalpan</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 7, 2011</lastchanged_date>
  <firstreceived_date>October 15, 2009</firstreceived_date>
  <firstreceived_results_date>April 28, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Swine Flu</keyword>
  <keyword>Flu</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Children</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>A/H1N1 2009 Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 29 sites in USA and Mexico</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial. The data entered is for the overall study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="P4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="165"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="148"/>
                <participants group_id="P3" count="146"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="164"/>
                <measurement group_id="B2" value="165"/>
                <measurement group_id="B3" value="160"/>
                <measurement group_id="B4" value="165"/>
                <measurement group_id="B5" value="654"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <sub_title>6 to &lt;36 Months age</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21.2" spread="7.9"/>
                <measurement group_id="B2" value="21.6" spread="8.8"/>
                <measurement group_id="B3" value="21.1" spread="8.4"/>
                <measurement group_id="B4" value="21.3" spread="8.9"/>
                <measurement group_id="B5" value="21.3" spread="8.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="75"/>
                <measurement group_id="B2" value="79"/>
                <measurement group_id="B3" value="80"/>
                <measurement group_id="B4" value="78"/>
                <measurement group_id="B5" value="312"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="89"/>
                <measurement group_id="B2" value="86"/>
                <measurement group_id="B3" value="80"/>
                <measurement group_id="B4" value="87"/>
                <measurement group_id="B5" value="342"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Responses After the First and Second Vaccinations</title>
        <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two-sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.
CHMP Criteria: Percentage of subjects with seroconversion for HI antibody is &gt;40%; percentage of subjects achieving an HI titer ≥1:40 is &gt; 70%; and the Geometric Mean Ratio (GMR) is &gt;2.5.</description>
        <time_frame>21 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="124"/>
                  <measurement group_id="O3" value="126"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Responses After the First and Second Vaccinations</title>
            <description>CBER guidance (&lt;65 years of age): The lower bound of the two-sided 95% CI for the percent of subjects achieving seroconversion for HI antibody should be ≥ 40% AND the lower bound of the two-sided 95% CI for the percent of subjects achieving an HI antibody titer ≥ 1:40 should be ≥ 70%.
CHMP Criteria: Percentage of subjects with seroconversion for HI antibody is &gt;40%; percentage of subjects achieving an HI titer ≥1:40 is &gt; 70%; and the Geometric Mean Ratio (GMR) is &gt;2.5.</description>
            <units>Percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>HI titer ≥1:40 (Day 22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79" lower_limit="71" upper_limit="86"/>
                  <measurement group_id="O2" value="37" lower_limit="29" upper_limit="46"/>
                  <measurement group_id="O3" value="86" lower_limit="78" upper_limit="91"/>
                  <measurement group_id="O4" value="50" lower_limit="41" upper_limit="59"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74" lower_limit="65" upper_limit="81"/>
                  <measurement group_id="O2" value="32" lower_limit="24" upper_limit="41"/>
                  <measurement group_id="O3" value="80" lower_limit="72" upper_limit="87"/>
                  <measurement group_id="O4" value="44" lower_limit="35" upper_limit="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O2" value="70" lower_limit="61" upper_limit="78"/>
                  <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O4" value="81" lower_limit="74" upper_limit="88"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="93" upper_limit="100"/>
                  <measurement group_id="O2" value="68" lower_limit="59" upper_limit="76"/>
                  <measurement group_id="O3" value="98" lower_limit="94" upper_limit="100"/>
                  <measurement group_id="O4" value="76" lower_limit="68" upper_limit="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Measurement by Geometric Mean Titers (GMT)</title>
        <description>The two-sided confidence intervals (CIs) were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667.(based on CBER guidance against the licensed comparator). Moreover the superiority hypothesis was tested using a margin of 1.</description>
        <time_frame>21 days after each vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the Full Analysis Set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="150"/>
                  <measurement group_id="O2" value="148"/>
                  <measurement group_id="O3" value="144"/>
                  <measurement group_id="O4" value="150"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunogenicity Measurement by Geometric Mean Titers (GMT)</title>
            <description>The two-sided confidence intervals (CIs) were calculated and assessed for non-inferiority first against the margin of 0.5 (exploratory margin) and in case of success against the margin of 0.667.(based on CBER guidance against the licensed comparator). Moreover the superiority hypothesis was tested using a margin of 1.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81" lower_limit="56" upper_limit="118"/>
                  <measurement group_id="O2" value="22" lower_limit="15" upper_limit="32"/>
                  <measurement group_id="O3" value="98" lower_limit="67" upper_limit="143"/>
                  <measurement group_id="O4" value="37" lower_limit="25" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT Day 43 (N=149,146,143,146)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="664" lower_limit="495" upper_limit="891"/>
                  <measurement group_id="O2" value="85" lower_limit="63" upper_limit="114"/>
                  <measurement group_id="O3" value="638" lower_limit="476" upper_limit="855"/>
                  <measurement group_id="O4" value="146" lower_limit="108" upper_limit="197"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>3.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.37</ci_lower_limit>
            <ci_upper_limit>5.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.43</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>ratio of GMTs</param_type>
            <param_value>4.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.85</ci_lower_limit>
            <ci_upper_limit>6.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 22.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.54</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.23</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.3</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Superiority of the adjuvanted vaccines against the non-adjuvanted vaccines was to be tested against the margin of 1 on day 43.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Ratios of GMTs</param_type>
            <param_value>4.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.09</ci_lower_limit>
            <ci_upper_limit>6.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for Day 22</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.54</ci_lower_limit>
            <ci_upper_limit>6.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for Day 22</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for Day 22</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.87</ci_lower_limit>
            <ci_upper_limit>7.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for day 22</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>2.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for Day 43</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>8.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.52</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for Day 43</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.94</ci_lower_limit>
            <ci_upper_limit>6.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for day 43</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>7.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.38</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority analysis for day 43</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority of adjuvanted vaccines was demonstrated against the non-adjuvanted vaccines in terms of antibody titers if the lower bound of the 2-sided 95% CI of GMT ratios were greater than 0.5 and also greater than 0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>4.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.87</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</title>
        <time_frame>Day 1 to 7</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was done on the safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                  <measurement group_id="O2" value="161"/>
                  <measurement group_id="O3" value="161"/>
                  <measurement group_id="O4" value="163"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local and Systemic Reactions After First Vaccination</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="8"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tenderness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="42"/>
                  <measurement group_id="O3" value="53"/>
                  <measurement group_id="O4" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="38"/>
                  <measurement group_id="O4" value="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="25"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="16"/>
                  <measurement group_id="O3" value="19"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persist crying</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="35"/>
                  <measurement group_id="O3" value="35"/>
                  <measurement group_id="O4" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever≥38.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</title>
        <time_frame>Day 22 to 28</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was done on the safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="155"/>
                  <measurement group_id="O2" value="148"/>
                  <measurement group_id="O3" value="157"/>
                  <measurement group_id="O4" value="157"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local and Systemic Reactions After Second Vaccination</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tenderness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="27"/>
                  <measurement group_id="O3" value="37"/>
                  <measurement group_id="O4" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="21"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="20"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="36"/>
                  <measurement group_id="O2" value="39"/>
                  <measurement group_id="O3" value="32"/>
                  <measurement group_id="O4" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in eating habits</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="18"/>
                  <measurement group_id="O3" value="14"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Persist crying</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="22"/>
                  <measurement group_id="O3" value="24"/>
                  <measurement group_id="O4" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever≥38.5°C</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                  <measurement group_id="O3" value="4"/>
                  <measurement group_id="O4" value="7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
        <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
        <time_frame>Past 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup of the per-protocol set(PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- No Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59-No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - No Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59-Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59-Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50) MF59-Previous Vaccinaiton</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59-Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                  <measurement group_id="O2" value="83"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="89"/>
                  <measurement group_id="O5" value="48"/>
                  <measurement group_id="O6" value="41"/>
                  <measurement group_id="O7" value="35"/>
                  <measurement group_id="O8" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Responses With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
            <description>Subgroup analysis based on receipt of recent seasonal vaccination. Comparison between subjects previously vaccinated versus not vaccinated with seasonal influenza vaccines.</description>
            <units>Percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Seroconversion (Day 22/Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="73" lower_limit="62" upper_limit="82"/>
                  <measurement group_id="O2" value="37" lower_limit="27" upper_limit="49"/>
                  <measurement group_id="O3" value="78" lower_limit="68" upper_limit="86"/>
                  <measurement group_id="O4" value="44" lower_limit="33" upper_limit="55"/>
                  <measurement group_id="O5" value="75" lower_limit="60" upper_limit="86"/>
                  <measurement group_id="O6" value="22" lower_limit="11" upper_limit="38"/>
                  <measurement group_id="O7" value="86" lower_limit="70" upper_limit="95"/>
                  <measurement group_id="O8" value="45" lower_limit="29" upper_limit="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion (Day 43/Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="93" upper_limit="100"/>
                  <measurement group_id="O2" value="66" lower_limit="55" upper_limit="76"/>
                  <measurement group_id="O3" value="98" lower_limit="92" upper_limit="100"/>
                  <measurement group_id="O4" value="78" lower_limit="67" upper_limit="86"/>
                  <measurement group_id="O5" value="96" lower_limit="86" upper_limit="99"/>
                  <measurement group_id="O6" value="71" lower_limit="54" upper_limit="84"/>
                  <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                  <measurement group_id="O8" value="73" lower_limit="56" upper_limit="85"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25" lower_limit="16" upper_limit="36"/>
                  <measurement group_id="O2" value="12" lower_limit="6" upper_limit="21"/>
                  <measurement group_id="O3" value="16" lower_limit="9" upper_limit="25"/>
                  <measurement group_id="O4" value="21" lower_limit="13" upper_limit="31"/>
                  <measurement group_id="O5" value="8" lower_limit="2" upper_limit="20"/>
                  <measurement group_id="O6" value="2" lower_limit="0.062" upper_limit="13"/>
                  <measurement group_id="O7" value="14" lower_limit="5" upper_limit="30"/>
                  <measurement group_id="O8" value="15" lower_limit="6" upper_limit="30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78" lower_limit="67" upper_limit="86"/>
                  <measurement group_id="O2" value="42" lower_limit="31" upper_limit="54"/>
                  <measurement group_id="O3" value="84" lower_limit="75" upper_limit="91"/>
                  <measurement group_id="O4" value="49" lower_limit="39" upper_limit="60"/>
                  <measurement group_id="O5" value="81" lower_limit="67" upper_limit="91"/>
                  <measurement group_id="O6" value="27" lower_limit="14" upper_limit="43"/>
                  <measurement group_id="O7" value="91" lower_limit="77" upper_limit="98"/>
                  <measurement group_id="O8" value="50" lower_limit="34" upper_limit="66"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O2" value="67" lower_limit="56" upper_limit="77"/>
                  <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O4" value="83" lower_limit="74" upper_limit="90"/>
                  <measurement group_id="O5" value="100" lower_limit="93" upper_limit="100"/>
                  <measurement group_id="O6" value="76" lower_limit="60" upper_limit="88"/>
                  <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                  <measurement group_id="O8" value="78" lower_limit="62" upper_limit="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
        <time_frame>Past 12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup on the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- No Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - No Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - No Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59-Previous Vaccination</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59-Previous Vaccination</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50) MF59-Previous Vaccinaiton</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59-with Previous Vaccination</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="81"/>
                  <measurement group_id="O2" value="83"/>
                  <measurement group_id="O3" value="92"/>
                  <measurement group_id="O4" value="89"/>
                  <measurement group_id="O5" value="48"/>
                  <measurement group_id="O6" value="41"/>
                  <measurement group_id="O7" value="35"/>
                  <measurement group_id="O8" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) With and Without Seasonal Influenza Vaccination for Year 2009 to 2010</title>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11" lower_limit="7.66" upper_limit="16"/>
                  <measurement group_id="O2" value="7.95" lower_limit="5.58" upper_limit="11"/>
                  <measurement group_id="O3" value="9.94" lower_limit="6.93" upper_limit="14"/>
                  <measurement group_id="O4" value="12" lower_limit="8.3" upper_limit="17"/>
                  <measurement group_id="O5" value="9.9" lower_limit="6.71" upper_limit="15"/>
                  <measurement group_id="O6" value="6.41" lower_limit="4.19" upper_limit="9.81"/>
                  <measurement group_id="O7" value="8.73" lower_limit="5.75" upper_limit="13"/>
                  <measurement group_id="O8" value="9.91" lower_limit="6.47" upper_limit="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101" lower_limit="61" upper_limit="167"/>
                  <measurement group_id="O2" value="25" lower_limit="15" upper_limit="41"/>
                  <measurement group_id="O3" value="105" lower_limit="63" upper_limit="173"/>
                  <measurement group_id="O4" value="42" lower_limit="26" upper_limit="68"/>
                  <measurement group_id="O5" value="78" lower_limit="42" upper_limit="145"/>
                  <measurement group_id="O6" value="17" lower_limit="8.65" upper_limit="33"/>
                  <measurement group_id="O7" value="107" lower_limit="55" upper_limit="207"/>
                  <measurement group_id="O8" value="44" lower_limit="22" upper_limit="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="975" lower_limit="663" upper_limit="1432"/>
                  <measurement group_id="O2" value="103" lower_limit="71" upper_limit="149"/>
                  <measurement group_id="O3" value="788" lower_limit="538" upper_limit="1154"/>
                  <measurement group_id="O4" value="186" lower_limit="129" upper_limit="271"/>
                  <measurement group_id="O5" value="388" lower_limit="226" upper_limit="666"/>
                  <measurement group_id="O6" value="57" lower_limit="32" upper_limit="103"/>
                  <measurement group_id="O7" value="486" lower_limit="273" upper_limit="868"/>
                  <measurement group_id="O8" value="124" lower_limit="69" upper_limit="223"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Response Based on Baseline Seropositivity</title>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- Baseline HI &lt;1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - HI &lt;1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59 - Baseline HI ≥1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59 - Baseline HI ≥1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="96"/>
                  <measurement group_id="O3" value="91"/>
                  <measurement group_id="O4" value="90"/>
                  <measurement group_id="O5" value="39"/>
                  <measurement group_id="O6" value="28"/>
                  <measurement group_id="O7" value="36"/>
                  <measurement group_id="O8" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Response Based on Baseline Seropositivity</title>
            <units>Percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Seroconversion (Day 22/Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="62" upper_limit="81"/>
                  <measurement group_id="O2" value="31" lower_limit="22" upper_limit="42"/>
                  <measurement group_id="O3" value="82" lower_limit="73" upper_limit="90"/>
                  <measurement group_id="O4" value="39" lower_limit="29" upper_limit="50"/>
                  <measurement group_id="O5" value="77" lower_limit="61" upper_limit="89"/>
                  <measurement group_id="O6" value="36" lower_limit="19" upper_limit="56"/>
                  <measurement group_id="O7" value="75" lower_limit="58" upper_limit="88"/>
                  <measurement group_id="O8" value="56" lower_limit="40" upper_limit="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion (Day 43/Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O2" value="67" lower_limit="56" upper_limit="76"/>
                  <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O4" value="77" lower_limit="67" upper_limit="85"/>
                  <measurement group_id="O5" value="92" lower_limit="79" upper_limit="98"/>
                  <measurement group_id="O6" value="71" lower_limit="51" upper_limit="87"/>
                  <measurement group_id="O7" value="94" lower_limit="81" upper_limit="99"/>
                  <measurement group_id="O8" value="74" lower_limit="58" upper_limit="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O3" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O4" value="0" lower_limit="0" upper_limit="4"/>
                  <measurement group_id="O5" value="62" lower_limit="45" upper_limit="77"/>
                  <measurement group_id="O6" value="39" lower_limit="22" upper_limit="59"/>
                  <measurement group_id="O7" value="56" lower_limit="38" upper_limit="72"/>
                  <measurement group_id="O8" value="64" lower_limit="47" upper_limit="79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 22)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="62" upper_limit="81"/>
                  <measurement group_id="O2" value="31" lower_limit="22" upper_limit="42"/>
                  <measurement group_id="O3" value="82" lower_limit="73" upper_limit="90"/>
                  <measurement group_id="O4" value="39" lower_limit="29" upper_limit="50"/>
                  <measurement group_id="O5" value="95" lower_limit="83" upper_limit="99"/>
                  <measurement group_id="O6" value="57" lower_limit="37" upper_limit="76"/>
                  <measurement group_id="O7" value="94" lower_limit="81" upper_limit="99"/>
                  <measurement group_id="O8" value="74" lower_limit="58" upper_limit="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O2" value="67" lower_limit="56" upper_limit="76"/>
                  <measurement group_id="O3" value="100" lower_limit="96" upper_limit="100"/>
                  <measurement group_id="O4" value="77" lower_limit="67" upper_limit="85"/>
                  <measurement group_id="O5" value="100" lower_limit="91" upper_limit="100"/>
                  <measurement group_id="O6" value="82" lower_limit="63" upper_limit="94"/>
                  <measurement group_id="O7" value="100" lower_limit="90" upper_limit="100"/>
                  <measurement group_id="O8" value="92" lower_limit="79" upper_limit="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
        <time_frame>up to Day 43</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59- Baseline HI &lt;1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59 - HI &lt;1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59 - HI &lt;1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O5">
            <title>3.75_(50)MF59 - Baseline HI ≥1:10</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O6">
            <title>7.5_(0)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O7">
            <title>7.5_(50)MF59 - Baseline HI ≥1:10</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O8">
            <title>15_(0)MF59 - Baseline HI ≥1:10</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                  <measurement group_id="O2" value="96"/>
                  <measurement group_id="O3" value="91"/>
                  <measurement group_id="O4" value="90"/>
                  <measurement group_id="O5" value="39"/>
                  <measurement group_id="O6" value="28"/>
                  <measurement group_id="O7" value="36"/>
                  <measurement group_id="O8" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) Based on Baseline Seropositivity</title>
            <units>Titres</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Day 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.06" lower_limit="4.98" upper_limit="5.14"/>
                  <measurement group_id="O2" value="5.07" lower_limit="4.99" upper_limit="5.15"/>
                  <measurement group_id="O3" value="5.01" lower_limit="4.93" upper_limit="5.09"/>
                  <measurement group_id="O4" value="5.06" lower_limit="4.98" upper_limit="5.14"/>
                  <measurement group_id="O5" value="53" lower_limit="34" upper_limit="83"/>
                  <measurement group_id="O6" value="35" lower_limit="21" upper_limit="58"/>
                  <measurement group_id="O7" value="47" lower_limit="29" upper_limit="76"/>
                  <measurement group_id="O8" value="69" lower_limit="44" upper_limit="108"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 22</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42" lower_limit="29" upper_limit="61"/>
                  <measurement group_id="O2" value="15" lower_limit="11" upper_limit="22"/>
                  <measurement group_id="O3" value="60" lower_limit="42" upper_limit="88"/>
                  <measurement group_id="O4" value="17" lower_limit="12" upper_limit="24"/>
                  <measurement group_id="O5" value="266" lower_limit="137" upper_limit="517"/>
                  <measurement group_id="O6" value="67" lower_limit="31" upper_limit="145"/>
                  <measurement group_id="O7" value="313" lower_limit="154" upper_limit="639"/>
                  <measurement group_id="O8" value="248" lower_limit="126" upper_limit="487"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 43</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="566" lower_limit="398" upper_limit="804"/>
                  <measurement group_id="O2" value="65" lower_limit="46" upper_limit="93"/>
                  <measurement group_id="O3" value="577" lower_limit="404" upper_limit="825"/>
                  <measurement group_id="O4" value="96" lower_limit="67" upper_limit="137"/>
                  <measurement group_id="O5" value="660" lower_limit="390" upper_limit="1117"/>
                  <measurement group_id="O6" value="167" lower_limit="90" upper_limit="308"/>
                  <measurement group_id="O7" value="811" lower_limit="462" upper_limit="1426"/>
                  <measurement group_id="O8" value="420" lower_limit="246" upper_limit="717"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Persistence 6 Months and 12 Months After the Second Vaccination</title>
        <time_frame>6 months and 12 months after second vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="124"/>
                  <measurement group_id="O3" value="127"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Persistence 6 Months and 12 Months After the Second Vaccination</title>
            <units>Percentage</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>HI titer ≥1:40 (Day 202, N=45,38,46,38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96" lower_limit="85" upper_limit="99"/>
                  <measurement group_id="O2" value="50" lower_limit="33" upper_limit="67"/>
                  <measurement group_id="O3" value="100" lower_limit="92" upper_limit="100"/>
                  <measurement group_id="O4" value="55" lower_limit="38" upper_limit="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion (Day 202, N=45,38,46,38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89" lower_limit="76" upper_limit="96"/>
                  <measurement group_id="O2" value="50" lower_limit="33" upper_limit="67"/>
                  <measurement group_id="O3" value="91" lower_limit="79" upper_limit="98"/>
                  <measurement group_id="O4" value="39" lower_limit="24" upper_limit="57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>HI titer ≥1:40 (Day 387, N=46,37,38,36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="85" lower_limit="71" upper_limit="94"/>
                  <measurement group_id="O2" value="27" lower_limit="14" upper_limit="44"/>
                  <measurement group_id="O3" value="84" lower_limit="69" upper_limit="94"/>
                  <measurement group_id="O4" value="36" lower_limit="21" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Seroconversion (Day 387, N=46,37,38,36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76" lower_limit="61" upper_limit="87"/>
                  <measurement group_id="O2" value="22" lower_limit="10" upper_limit="38"/>
                  <measurement group_id="O3" value="76" lower_limit="60" upper_limit="89"/>
                  <measurement group_id="O4" value="25" lower_limit="12" upper_limit="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Persistence by Geometric Mean Titers (GMT)</title>
        <time_frame>6 months and 12 months after second vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was done on the subgroup of the per-protocol set (PPS).</population>
        <group_list>
          <group group_id="O1">
            <title>3.75_(50)MF59</title>
            <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O2">
            <title>7.5_(0)MF59</title>
            <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O3">
            <title>7.5_(50)MF59</title>
            <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
          <group group_id="O4">
            <title>15_(0)MF59</title>
            <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="129"/>
                  <measurement group_id="O2" value="124"/>
                  <measurement group_id="O3" value="126"/>
                  <measurement group_id="O4" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Antibody Persistence by Geometric Mean Titers (GMT)</title>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>GMT (Day 1)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10" lower_limit="7.94" upper_limit="14"/>
                  <measurement group_id="O2" value="7.27" lower_limit="5.5" upper_limit="9.6"/>
                  <measurement group_id="O3" value="9.29" lower_limit="7.06" upper_limit="12"/>
                  <measurement group_id="O4" value="11" lower_limit="8.2" upper_limit="14"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT (Day 202, N=45, 38, 46, 38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="176" lower_limit="111" upper_limit="280"/>
                  <measurement group_id="O2" value="33" lower_limit="20" upper_limit="54"/>
                  <measurement group_id="O3" value="205" lower_limit="133" upper_limit="316"/>
                  <measurement group_id="O4" value="42" lower_limit="25" upper_limit="69"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>GMT (Day 387, N= 46, 37, 38, 36)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="92" lower_limit="52" upper_limit="162"/>
                  <measurement group_id="O2" value="15" lower_limit="8.24" upper_limit="28"/>
                  <measurement group_id="O3" value="85" lower_limit="48" upper_limit="151"/>
                  <measurement group_id="O4" value="25" lower_limit="13" upper_limit="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the entire study period.</time_frame>
      <desc>Data provided in the &quot;Other Adverse Events (&gt;5%)&quot; includes solicited local and systemic reactions along with unsolicited AEs that persisted for more than 7 days after each study vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>3.75_(50)MF59</title>
          <description>3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E2">
          <title>7.5_(0)MF59</title>
          <description>7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E3">
          <title>7.5_(50)MF59</title>
          <description>7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
        <group group_id="E4">
          <title>15_(0)MF59</title>
          <description>15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="137" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injections site hemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Croup infections</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="162"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="162"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
